SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study.

D'heygere, François

SVR24 rates in patients with HCV genotype 5 and 6 infection treated with peginterferon alfa-2a (40KD) plus ribavirin: results from the real world PROPHESYS study. [electronic resource] - Annals of hepatology - 303-4 p. digital

Publication Type: Letter; Multicenter Study; Research Support, Non-U.S. Gov't

1665-2681


Antiviral Agents--therapeutic use
Cohort Studies
Dose-Response Relationship, Drug
Drug Therapy, Combination
Female
Genotype
Hepacivirus--genetics
Hepatitis C--blood
Humans
Interferon-alpha--therapeutic use
International Cooperation
Male
Middle Aged
Polyethylene Glycols--therapeutic use
Pragmatic Clinical Trials as Topic
RNA, Viral--blood
Recombinant Proteins--therapeutic use
Ribavirin--therapeutic use
Treatment Outcome
Viral Load